Tagraxofusp: Phase 1 Study (+/- chemotherapy) in Pediatric Patients with R/R CD123 expressing Heme Malignancies
Phase I Study of Tagraxofusp +/- Chemotherapy in Pediatric Patients with R/R CD123-Expressing Hematologic Malignancies: A TACL Consortium Trial. ASH 2022. Poster
Tagraxofusp: Patients with BPDCN and Prior/Concomitant Hem Malignancies: Subgroup Analysis of Pivotal Trial
Patients with BPDCN and Prior/Concomitant Hem Malignancies: Subgroup Analysis of Pivotal Trial. ASH 2022. Poster
Tagraxofusp: Preliminary Results from an Observational Study of Patients with BPDCN Treated in the European EAP
Preliminary Results from an Observational Study of Patients with BPDCN Treated in the European EAP. ASH 2022. Poster
Tagraxofusp: Phase 1/2 Study of Tagraxofusp in Patients with Relapsed/Refractory MF
Tagraxofusp: Phase 1/2 Study of Tagraxofusp in Patients with Relapsed/Refractory MF. ASH 2021. Oral Presentation
Tagraxofusp in Patients with Chronic Myelomonocytic Leukemia (CMML): Updated Results of an Ongoing Phase 1/2 Trial
TAG in Patients with CMML: Updated Results from Phase 1/2 Trial. ASH 2021. Oral Presentation
Tagraxofusp: Subanalysis of Pivotal Trial in BPDCN by Age and Baseline Disease
Tagraxofusp Subanalysis of Pivotal Trial in BPDCN by Age and Baseline Disease. ASH 2021. Oral Presentation
Tagraxofusp: Safety and Efficacy of Combing TAG with AZA and AZA+VEN
Safety and Efficacy of Combining Tagraxofusp with AZA or AZA+VEN in a Phase 1b Study for CD123 Positive AML, MDS, or BPDCN. ASH 2021. Poster
Tagraxofusp: A Multicenter Phase 1/2 Trial in Patients with Poor-Risk MF
A Multicenter Phase 1/2 Trial of Tagraxofusp in Patients with Poor-Risk MF. ASH 2020. Poster
Tagraxofusp Alone and in Combination with Ruxolitinib for Treatment of Myeloproliferative Neoplasms
Evaluation of Tagraxofusp(SL-401) Alone and in Combination with Ruxolitinib for the Treatment of Myeloproliferative Neoplasms. ASH 2019. Poster
Results from Clinical Trial of Tagraxofusp in Patients with Intermediate or High Risk R/R MF
Results from Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis. ASH 2019. Oral Presentation